

## Allison Betof Warner, MD, PhD Curriculum Vitae

Name: Betof Warner, Allison

Signature: 

Date of Preparation: 03/10/2023

### A. PERSONAL DATA

Office address:	Stanford Cancer Center 900 Blake Wilbur Dr. Stanford, CA 94305
Office telephone:	(650) 724-9707
Office fax:	(650) 724-1445
Home address:	350 Sharon Park Dr. Apt A21 Menlo Park, CA 94025
Cell phone:	215-208-3677
Email address - Work:	<a href="mailto:allison.betof@stanford.edu">allison.betof@stanford.edu</a>
Email address - Personal:	allison.betof@gmail.com

### B. EDUCATION

#### Academic Degree(s)

Degree	Institution Name & Location	Dates Attended	Year Awarded
BA	Cornell University - Ithaca, NY	8/2001 – 5/2005	2005
MD	Duke University School of Medicine -Durham, NC	8/2005 – 5/2013	2013
PhD	Duke University School of Medicine -Durham, NC	8/2005 – 5/2013	2013

### C. POSTDOCTORAL TRAINING

Title (include area of training)	Institution Name & Location	Dates
Intern Physician in Internal Medicine	Massachusetts General Hospital - Boston, MA	06/2013 – 06/2014
Resident Physician in Internal Medicine	Massachusetts General Hospital - Boston, MA	07/2014 – 06/2016
Fellow in Medical Oncology	Memorial Sloan Kettering Cancer Center New York, NY	07/2016 – 06/2019

**D. PROFESSIONAL POSITIONS & EMPLOYMENT****Academic Appointments**

<b>Title</b>	<b>Institution, City and State</b>	<b>Dates Attended</b>
Clinical Instructor (Awaiting formal appointment as Assistant Professor)	Stanford University School of Medicine Palo Alto, CA	03/2023 - present
Assistant Member (Level I)	Memorial Sloan Kettering Cancer Center - New York, NY	07/2019 - 02/2023
Instructor in Medicine	Weill Cornell Medical College - New York, NY	07/2019 - 02/2023

**Hospital Appointments**

<b>Title</b>	<b>Institution, City and State</b>	<b>Dates Attended</b>
Clinical Instructor (Awaiting formal appointment as Assistant Professor)	Stanford Hospital/Lucile Packard Children's Hospital at Stanford; Palo Alto, CA	03/2023 - present
Assistant Attending Physician	Memorial Hospital for Cancer and Allied Diseases; New York, NY	07/2019 – 02/2023

**Other Professional Positions & Employment**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Director, Melanoma Program Director, Solid Tumor Cellular Therapy Leader, Melanoma Clinical Research Group Principal Investigator, Betof Laboratory Co-Leader, Pigmented Lesion Clinic	Stanford University School of Medicine Palo Alto, CA 94025	03/2023 - present

**E. LICENSURE, BOARD CERTIFICATION****Licensure**

<b>State</b>	<b>Number</b>	<b>Date of Issue</b>	<b>Date of Expiration</b>
CA	A184101	02/05/2023	02/28/2025
NJ	25MA11203500	07/21/2021	06/30/2023
NY	283244	02/29/2016	07/01/2023

<b>DEA number:</b>	FB8876281
<b>NPI number:</b>	1174961908

**Board Certification**

<b>Full Name of Board</b>	<b>Certificate # (indicate if board eligible)</b>	<b>Dates of Certification</b>
American Board of Internal Medicine; Internal Medicine Certification Exam	373475	08/16/2016 - 12/31/2026
American Board of Internal Medicine; Medical Oncology Certification Exam	373475	10/31/2018 – 12/31/2028

**F. INSTITUTIONAL/HOSPITAL AFFILIATION**

Primary Hospital Affiliation:	Stanford Hospital
Other Hospital Affiliations:	Lucile Packard Children's Hospital at Stanford
Other Institutional Affiliations:	Stanford University School of Medicine

**G. EMPLOYMENT STATUS**

<b>Name of Current Employer(s):</b>	Stanford University School of Medicine
<b>Current Employment Status:</b>	Full-time salaried

**H. HONORS, AWARDS**

<b>Name of Award</b>	<b>Organization</b>	<b>Date Awarded</b>
Newton-Wellesley Hospital Department of Medicine Teaching Commendation	Newton-Wellesley Hospital	05/2016
Society for Translational Oncology Fellows Award	Society for Translational Oncology	10/2017
Conquer Cancer Foundation of ASCO Young Investigator Award	Conquer Cancer Foundation of ASCO	06/2018
Finalist, The Oncologist Young Investigator Award	The Oncologist	11/2018
MSKCC Housestaff Didactic Teaching Award	Memorial Sloan Kettering Cancer Center	06/2019
MSKCC Certificate for Teaching Excellence	Memorial Sloan Kettering Cancer Center	06/2021
Conquer Cancer Foundation of ASCO Career Development Award	Conquer Cancer Foundation of ASCO	06/2022

40 Under 40 in Cancer Award	40 Under 40 in Cancer	06/2022
-----------------------------	-----------------------	---------

**I. PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS**

Organization	Date
American Association for Cancer Research	2012 - Present
American Society of Clinical Oncology	2015 - Present
Society for Immunotherapy of Cancer	2019 - Present
American College of Sports Medicine	2019 - Present
European Society for Medical Oncology	2021 - Present

**J. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

Activity	Percent Effort (%)
Teaching	2%
Clinical	30%
Administrative	8%
Research	60%
Total	100%

**K. EDUCATIONAL CONTRIBUTIONS**

**Didactic teaching**

Title	Audience	Dates
MSKCC Melanoma Disease Management Team Conference	MSK Melanoma DMT	10/2017
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	02/16/2018
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	06/20/2018
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	07/23/2018
MSKCC Research in Progress Grand Rounds	MSK	07/27/2018
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	08/07/2018

MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	09/06/2018
MSKCC Melanoma Disease Management Team Conference	MSK Melanoma DMT	09/14/2018
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	02/20/2019
Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	12/03/2019
Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	01/21/2020
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	04/2020
Weill Cornell Clinical Trials K30 Course Lecture	WCM	04/30/2020
MSKCC Summer Student Lecture Series, Melanoma Disease Management Team, MSKCC Housestaff Lectures	MSK	07/2020
MD Anderson Cancer Center Melanoma Medical Oncology Grand Rounds (invited)	MD Anderson	08/05/2020
Brain Metastasis Working Group	MSK	10/26/2020
Adolescent and Young Adult Interdisciplinary Team Meeting	MSK	11/11/2020
MSK Nocturnist Lecture Series	MSK	04/08/2021
Weill Cornell Clinical Trials K30 Course Lecture	WCM	04/22/2021
MSKCC Housestaff Lecture (Transitional Year Bootcamp)	MSK	8/12/2021
MSKCC Housestaff Lecture (Transitional Year Bootcamp)	MSK	10/25/2021
Brain Metastasis Working Group	MSK	12/9/2021
MSKCC Fellow Board Review Lecture	MSK	8/10/2022
Roswell Park Cancer Center Medical Grand Rounds	Roswell Park	9/2/2022
MUSC Exercise Oncology Course Lecture	MUSC	10/21/2022

### Clinical teaching

Title	Audience	Dates
Precepting MSK fellows in clinic	Fellows	07/2020 – 02/2023
Precepting Weill Cornell medical students in clinic	Medical students	02/2021 – 02/2023

### Administrative teaching

Title	Audience	Dates
Course Director, MSK Department of Medicine Grand Rounds	MSK	09/2020 – 10/1/2022

### Continuing education and professional education as teacher

Title	Audience	Dates
Management of Treatment-Related Adverse Events Symposium (Continuing Medical Education Course, lecturer)	CME	10/18/2019 - 10/18/2019
Contemporary Management of Complex Skin Cancers 2019 (Continuing Medical Education Course, lecturer)	CME	11/02/2019 - 11/02/2019
Contemporary Management of Complex Skin Cancers 2020 (Continuing Medical Education Course, lecturer)	CME	10/2020 - 10/2020
Management of Treatment-Related Adverse Events Symposium (Continuing Medical Education Course, lecturer)	CME	10/2020 - 10/2020
Contemporary Management of Complex Skin Cancers 2022 (Continuing Medical Education Course, lecturer)	CME	11/2022 – 11/2022

### Community education or patient outreach

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Movement is Medicine: The Role of Exercise in Melanoma Care	AIM at Melanoma Living with Melanoma Symposium	10/02/2019
Movement is Medicine: The Role of Exercise in Melanoma Care	Northwest Melanoma Patient Symposium	04/10/2021
Movement is Medicine: The Role of Exercise in Melanoma Care	Melanoma Research Alliance Patient Forum	03/08/2023

### L. CLINICAL PRACTICE, INNOVATION, and LEADERSHIP

#### Clinical Practice

Duration	Name/Location of Practice	Type of Activity	Level of Activity
03/2023 – present	Pigmented Lesion Clinic/ Stanford Healthcare	Ambulatory practice + inpatient attending	3 sessions per week
2019 - 02/2023	Melanoma Clinic, Early Drug Development Clinic/ Memorial Sloan Kettering Cancer Center	Ambulatory practice	2 sessions per week
2021 - 02/2023	Cellular Therapy Service Clinic/ Memorial Sloan Kettering Cancer Center	Ambulatory practice	1 session per week

#### Clinical Innovations

<i>Date Innovation Launched</i>	<i>Title/Location of Innovation</i>	<i>Role</i>	<i>Short Description of the influence on clinical care or practice management</i>
N/A			

#### Clinical Leadership

<i>Years</i>	<i>Leadership Role</i>	<i>Short Description of activity/program</i>
03/2023 – present	Director, Melanoma Program Director, Solid Tumor Cellular Therapy Co-Director, Pigmented Lesion Clinic	Stanford University Cutaneous Oncology Program

## **M. RESEARCH**

I am a translational clinician-investigator with both laboratory and clinical trial expertise in tumor immunology and microenvironment. My research focuses on improving the efficacy immunotherapy treatment by leading clinical trials of immunotherapy in difficult-to-treat subsets of melanoma, including those patients whose disease is refractory to standard immune checkpoint inhibitors and patients with central nervous system metastases. As a junior faculty member, I have built the foundation for a strong clinical trial portfolio and deep collaborations with laboratory-based investigators. I have been integrally involved in clinical trial design and management of melanoma patients on clinical studies. At Memorial Sloan Kettering, I took leadership of the Melanoma Service's research on central nervous system (CNS) metastasis and developed a cellular therapy program for melanoma. My involvement with these projects has enabled me to establish strong collaborative relationships with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, pathology and several translational laboratories and facilitated my recent appointment as Director of the Melanoma Program and Director of Solid Tumor Cellular Therapy within the Division of Oncology at Stanford University School of Medicine.

### **Research Activities:**

<b>IRB #</b>	<b>Title</b>	<b>Dates start-end</b>	<b>PI</b>	<b>My Role</b>
19-234	A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors	10/07/2019-04/10/2020	Allison Betof Warner	PI
19-290	Evaluating Retreatment Efficacy and Toxicity in Melanoma Patients	08/09/2019-08/04/2020	Allison Betof Warner	PI
20-065	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis	06/05/2020-11/17/2021	Allison Betof Warner	PI
20-387	Five-year Survival with Immune Checkpoint Inhibitors in Advanced Melanoma	08/28/2020-present	Allison Betof Warner	PI
20-400	Tumor Mutation Burden and Immune Related Adverse Events in Melanoma Patients	09/08/2020-02/2023	Allison Betof Warner	PI
20-471	Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (EA6141) (CIRB)	11/17/2020-02/2023	Allison Betof Warner	PI

20-519	A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) (EA6192) (CIRB)	12/14/2020-02/2023	Allison Betof Warner	PI
21-098	A Phase 1, First in Human Study of DS-1055a in Subjects with Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors	07/27/2021-02/2023	Allison Betof Warner	PI
21-136	Effects of Diabetes and Oral Diabetes Therapy on Melanoma Outcomes	04/01/2021-present	Allison Betof Warner	PI
22-198	An Expanded Access Program of Lifileucel, Autologous Tumor Infiltrating Lymphocytes (TIL LN-144), for Patients with Unresectable or Metastatic Melanoma (EAP)	06/17/2022-02/2023	Allison Betof Warner	PI
22-230	A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer	08/26/2022-02/2023	Allison Betof Warner	PI
22-322	A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients with Asymptomatic Melanoma Brain Metastases	11/25/2022-02/2023	Allison Betof Warner	PI
13-187	A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors	10/21/2013-02/2023	Callahan	Co-PI
13-198	A Phase 1 Study to Evaluate the Safety and Tolerability of anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects With Advanced Solid Tumors	11/26/2013-02/08/2022	Callahan	Co-PI
20-096	Evaluation of Melanoma Patients who Received More Than 1 Course of Therapy with Ipilimumab/Nivolumab Combination	03/11/2020-02/2023	Chapman	Co-PI
20-154	A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/ LN-145/LN-145-S1) in Patients with Solid Tumors	07/23/2020-02/2023	Schoenfeld	Co-PI
20-204	Characterization of Melanoma Patients with COVID19 Infection (COVID)	06/18/2020-05/13/2022	Chapman	Co-PI
20-442	Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis (EAQ172) (CIRB)	12/07/2020-03/10/2022	Beattie	Co-PI
21-121	An Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1 Targeting CD3 T-Cell Engager in Participants with Metastatic Melanoma	03/26/2021-06/30/2022	Callahan	Co-PI



21-124	Inpatient Immunotherapy for Advanced Melanoma	03/16/2021-02/2023	Postow	Co-PI
21-286	A Multicenter, Open Label, Phase 2 Study of Intratumoral CMP-001 in Combination with Intravenous Nivolumab in Subjects with Refractory Unresectable or Metastatic Melanoma	11/19/2021-02/2023	Shoushtari	Co-PI
21-332	A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer	09/21/2021-02/2023	Callahan	Co-PI
21-384	Association of Exercise with Response to Immunotherapy in Patients with Cancer	09/22/2021-02/2023	Jones	Co-PI
21-418	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors	03/10/2022-02/2023	Callahan	Co-PI
22-109	A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients with Metastatic Uveal Melanoma	11/1/2022-02/2023	Shoushtari	Co-PI
22-132	A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab	05/10/2022-02/2023	Shoushtari	Co-PI
22-151	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients with Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6	06/24/2022-02/2023	Shoushtari	Co-PI
22-202	A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma (A091903) (CIRB)	06/17/2022-02/2023	Shoushtari	Co-PI

**Research Support:**

**Current Research Funding**

Award Source:(funding agency - federal, foundation, industry; type of grant)*	Conquer Cancer Foundation of ASCO
Project title:	A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (Lifileucel) for Patients with Asymptomatic Melanoma Brain Metastases
Duration of support:	07/2022 – 06/2025
Name of Principal Investigator:	Betof Warner

The major goals of this project are:	The goal of this project is to complete a pilot study to rigorously define the feasibility of manufacturing and successfully treating patients with melanoma brain metastases (MBM) with lifileucel. This will be the first study to specifically evaluate lifileucel for active MBM. Establishing feasibility and safety of this approach could rapidly lead to larger phase II efficacy and combination trials, which have the potential to change treatment paradigms and improve outcomes from this dreaded complication of melanoma. We have proposed extensive correlative analyses on blood and cerebrospinal fluid to enhance our mechanistic understanding of the baseline tumor microenvironment of MBM and immunologic and genomic changes during the course of TIL therapy.
--------------------------------------	---

Award Source:(funding agency - federal, foundation, industry; type of grant)*	NIH- K12 Paul Calabresi Career Development Award for Clinical Oncology
Project title:	A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (Lifileucel) for Patients with Asymptomatic Melanoma Brain Metastases
Duration of support:	09/2022 – 02/28/2023
Name of Principal Investigator:	Betof Warner
The major goals of this project are:	The goal of this project is to complete a pilot study to rigorously define the feasibility of manufacturing and successfully treating patients with melanoma brain metastases (MBM) with lifileucel. This will be the first study to specifically evaluate lifileucel for active MBM. Establishing feasibility and safety of this approach could rapidly lead to larger phase II efficacy and combination trials, which have the potential to change treatment paradigms and improve outcomes from this dreaded complication of melanoma. We have proposed extensive correlative analyses on blood and cerebrospinal fluid to enhance our mechanistic understanding of the baseline tumor microenvironment of MBM and immunologic and genomic changes during the course of TIL therapy.

Award Source:(funding agency - federal, foundation, industry; type of grant)*	Melanoma Research Foundation Career Development Award
Project title:	A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (Lifileucel) for Patients with Asymptomatic Melanoma Brain Metastases
Duration of support:	09/2022 – 08/2024
Name of Principal Investigator:	Betof Warner
The major goals of this project are:	The goal of this project is to complete a pilot study to rigorously define the feasibility of manufacturing and successfully treating patients with melanoma brain metastases (MBM) with lifileucel. This will be the first study to specifically evaluate lifileucel for active MBM. Establishing feasibility and safety of this approach could rapidly lead to larger phase II efficacy and combination trials, which have the potential to change treatment paradigms and improve outcomes from this dreaded complication of melanoma. We have proposed extensive correlative analyses on blood and cerebrospinal fluid to enhance our mechanistic understanding of the baseline tumor

	microenvironment of MBM and immunologic and genomic changes during the course of TIL therapy.
--	---

Award Source:(funding agency - federal, foundation, industry; type of grant)*	Imaging and Radiation Sciences Program Seed Grant
Project title:	Imaging and Radiation Sciences Program (IMRAS)
Duration of support:	09/2021 - 08/2023
Name of Principal Investigator:	Betof Warner
The major goals of this project are:	The efficacy of proton craniospinal irradiation plus immune checkpoint blockade in melanoma leptomeningeal disease (LMD)- identifying genomic, immune, and microenvironmental biomarkers predictive of clinical benefit

Award Source:(funding agency - federal, foundation, industry; type of grant)*	lovance Biotherapeutics
Project title:	A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (Lifileucel) for Patients with Asymptomatic Melanoma Brain Metastases
Duration of support:	11/2022– 02/2023
Name of Principal Investigator:	Betof Warner
The major goals of this project are:	The goal of this project is to complete a pilot study to rigorously define the feasibility of manufacturing and successfully treating patients with melanoma brain metastases (MBM) with lifileucel. This will be the first study to specifically evaluate lifileucel for active MBM. Establishing feasibility and safety of this approach could rapidly lead to larger phase II efficacy and combination trials, which have the potential to change treatment paradigms and improve outcomes from this dreaded complication of melanoma.

Award Source:(funding agency - federal, foundation, industry; type of grant)*	Daiichi Sankyo
Project title:	A Phase 1, First in Human Study of DS-1055a in Subjects with Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Duration of support:	01/2021 - 02/2023
Name of Principal Investigator:	Betof Warner, Allison
The major goals of this project are:	To assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose of DS-1055a for further investigation

Award Source:(funding agency - federal, foundation, industry; type of grant)*	LEAP Therapeutics
---	-------------------

Project title:	A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Duration of support:	05/2019 - 02/2023
Name of Principal Investigator:	Betof Warner, Allison
The major goals of this project are:	To assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose of TRX518 in combination with cyclophosphamide and avelumab

Award Source:(funding agency - federal, foundation, industry; type of grant)*	ABPI
Project title:	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Duration of support:	09/2019 - 02/2023
Name of Principal Investigator:	Betof Warner, Allison
The major goals of this project are:	To assess the efficacy and safety of high-dose encorafenib+binimetinib for patients with melanoma brain metastases with a BRAFV600 mutation

#### Past (Completed) Funding:

Award Source:(funding agency - federal, foundation, industry; type of grant)*	MSK MIND
Project title:	MSK MIND 2020 - Callahan: Defining immunologic factors associated with response or toxicity after checkpoint blockade.
Duration of support:	04/2021 - 03/2022
Name of Principal Investigator:	Margaret Callahan
The major goals of this project are:	AIM 1. Use pre-treatment peripheral blood markers to predict toxicity to ICB. AIM 2. Test the validity of our novel response biomarker in a pan cancer population . AIM 3. Characterize the pharmacodynamic effects of ICB and relationship to toxicity and response.

Pending Funding: N/A

#### Patents & Inventions

<i>Inventors</i>	<i>Title of Invention</i>	<i>Patent Number</i>
N/A		

#### N. MENTORING

##### Current Mentees

Name	Lee, Sejin
Site/Position	Remote- University of North Carolina / Thesis Committee Member

Expected Period	07/2019 – present
Project/Accomplishments**	Real-world treatment patterns and outcomes for patients with advanced melanoma: immunotherapy versus targeted therapy
Goals/expected Outcomes	Successful PhD dissertation defense 3/15/2022; final dissertation approval and publications ongoing
Type of Supervision (Research, clinical, teaching, leadership)	Research

Name	Loo, Kimberly
Site/Position	MSK and Cornell University / Mentor for resident research project
Expected Period	09/2020 - present
Project/Accomplishments**	Loo K, Smithy JW, Postow MA, Betof Warner A. Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma. <i>Frontiers in Immunology</i> . 2022. <a href="https://doi.org/10.3389/fimmu.2021.810388">https://doi.org/10.3389/fimmu.2021.810388</a>  Loo K, Goldman D, Panageas K, Callahan MK, Chapman PB, Momtaz P, Shoushtari AN, Wolchok JD, Postow MA, Betof Warner A. Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB). ASCO 2021 Annual Meeting. <i>J Clin Oncol</i> 39, 2021 (suppl 15; abstr 9534)
Type of Supervision (Research, clinical, teaching, leadership)	Research

#### O. INSTITUTIONAL LEADERSHIP ACTIVITIES

<i>Role(s)/Position</i>	<i>Institution/Location</i>	<i>Dates</i>
Director, Melanoma Program Director, Solid Tumor Cellular Therapy Leader, Melanoma Clinical Research Group Principal Investigator, Betof Laboratory	Stanford University School of Medicine; Palo Alto, CA	02/2023-present

#### P. INSTITUTIONAL ADMINISTRATIVE ACTIVITIES

<b>Name of Committee</b>	<b>Role</b>	<b>Dates</b>
Scientific Review Committee, Stanford University School of Medicine	Member	03/2023 - present
Memorial Sloan Kettering Center Junior Faculty Council	Member	2020 – 11/2022

#### Q. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

##### Leadership in Extramural Organizations

<i>Organization</i>	<i>Role</i>	<i>Dates</i>
N/A		

### Service on Boards and/or Committees

#### Regional

<i>Name of Committee</i>	<i>Role</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
N/A			

#### National

<i>Name of Committee</i>	<i>Role</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
Neuro irAE Disease Definition Panel	Member	(Delphi consensus process facilitated by Massachusetts General Hospital)	10/2020-11/2021
Dermatologic irAE Disease	Member		06/2021-
Cancer.Net Editorial Board	Advisory Panelist		11/2021-

#### International

<b>Name of Committee</b>	<b>Role</b>	<b>Organization Institution/Location</b>	<b>Dates</b>
American Association for Cancer Research Associate Member Council	Member (2016-2020) Chair (2018-2019)	AACR	2016-2020
American Society of Clinical Oncology -Society for Immunotherapy of Cancer (SITC) Immuno-Oncology Symposium Program Committee	Committee Member	ASCO and SITC	04/2019-01/2022
Eastern Cooperative Oncology Group-ACRIN Melanoma Cancer Research Group	Member	ECOG-ACRIN	08/2020-Present
TIL Cell Therapy Working Group	Member	TIL Cell Therapy Working Group	10/2020-Present
SITC Early Career Scientist Committee	Committee Member	SITC	02/2021-Present
ASCO Plenary Series Scientific Review Committee- Melanoma/Skin Cancers Track	Committee Member	ASCO	07/2021-06/2025
Conquer Cancer Foundation Scientific & Career Development Retreat Program Committee	Committee Member	Conquer Cancer Foundation of ASCO	12/2021

#### Grant Reviewing/Study Sections

<i>Role(s)</i>	<i>Organization Name</i>	<i>Dates</i>
Grant Reviewer	Melanoma Research Foundation	04/2022
Grant Reviewer	Melanoma Research Program (MRP) for the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP)	11/2022

**Editorial Activities**

	Dates
Journal Reviewing/ad hoc reviewing	
Clinical Science	07/2017-Present
Health Science Reports	07/2017-Present
Molecular Metabolism	07/2017-Present
Pigment Cell & Melanoma Research	07/2017-Present
JAMA Dermatology	07/2017-Present
Oncolmunology	07/2017-Present
Therapeutic Advances in Medical Oncology	07/2017-Present
Cancer Immunology Research	07/2017-Present
The Oncologist	07/2017-Present
Annals of Oncology	07/2017-Present
Clinical Cancer Research	07/2017-Present
Journal for ImmunoTherapy of Cancer	07/2017-Present
Journal of Clinical Oncology	01/2020-Present
International Journal of Hyperthermia	07/2020- Present
New England Journal of Medicine	08/2022-Present
New England Journal of Medicine Evidence	10/2022- Present

**Editor/Co-Editor**

<i>Books / Textbooks / Journals / Organization Name</i>	Dates
N/A	

**Editorial Board Membership**

Board / Organization Name	Dates
N/A	

**R. INVITED AND/OR PEER-SELECTED PRESENTATIONS****Regional**

Title	Institution/Location	Dates
Early Career Hill Day, New York State Representative	American Association for Cancer Research / Washington DC	2018

**National**

Title	Institution/Location	Dates
Incorporating Clinical Practice Guidelines for Managing Immune-Related Adverse Events	ASCO Palliative and Supportive Care in Oncology Symposium /San Diego, CA	2018
(1) From Mice to Man: Preclinical Data for the Efficacy of Exercise as Anti-Cancer Therapy (2) Discussant, Oncology Clinical Cases	American College of Sports Medicine Annual Meeting / Orlando, FL	2019

Recognizing, Understanding, and Overcoming Toxicities from Immune Checkpoint Inhibitors	Best of ASCO Bellevue / Seattle, WA	2019
Movement is Medicine: The Role of Exercise in AYA Cancer Care	DFCI/MSKCC Adolescent & Young Adult Oncology Research Symposium / Boston, MA	2020
Recognizing, Understanding, and Overcoming Toxicities in the Targeted and Immune Therapy Era	NCODA National Spring Forum /Remote-Dallas, TX	2020
Cancer in the Time of COVID-19, The MSKCC Experience	MD Anderson Cancer Center Melanoma Grand Rounds / Remote- Houston, TX	2020
How I Manage Immune-Related Adverse Events	38th Annual CFS: Innovative Cancer Therapy for Tomorrow / Virtual	2020
TIL Therapy in Melanoma: The Future is Now	Stanford Cancer Institute Retreat/ Palo Alto, CA	9/2022
Exercise as a Therapeutic Strategy for Cancer: Biological Mechanisms and Clinical Outcomes	American College of Sports Medicine Integrative Physiology of Exercise Conference/ Baltimore, MD	9/2022

### International

Title	Institution/Location	Dates
The role of metabolism in immune response in tumors: merging the past and the present of tumor microenvironment	Immuno-Oncology Summit / Boston, MA	2017
Therapeutic manipulation of Tumor Microenvironment to Improve Immune Response in Tumors	Immuno-Oncology Summit / Boston, MA	2018
Clinical Issues in Patients Treated with Immune Checkpoint Blockade: Challenges and Controversies; DEBATE: How long should we treat with PD-1? We should treat all patients with PD-1 for at least two years, possibly forever.	MSK CME / New York, NY	2019
Therapeutic Manipulation of the Tumor Microenvironment to Enhance Response to Immunotherapy	LG Chem Life Science Symposium / Boston, MA	2019
Contemporary Management of Complex Skin Cancers	MSK CME / New York, NY	2019
Therapeutic Manipulation of the Tumor Microenvironment to Enhance Response to Immunotherapy	PEGS Summit / Virtual	2020
Long-Term Outcomes and Responses to Retreatment in Melanoma patients Treated with PD-1 Blockade	Immuno-Oncology Summit / Virtual	2020
Who Gets Adjuvant Therapy in Melanoma?	MSK CME / New York, NY	2020



Cyclophosphamide Chemotherapy Enhances Anti-Tumor Effects of Immune Checkpoint Inhibition in Mouse Models of Immunotherapy-Refractory Melanoma	ECOG-ACRIN Young Investigator Symposium / Virtual	2020
“Exercise as an (Adjunct Immunotherapy)? Evidence of Therapeutic Manipulation of the Tumor Microenvironment”	Society for Thermal Medicine Virtual Symposium / Virtual	2021
Case-Based Panel, Surviving Sarcoma and Living a Healthy Life	ASCO Annual Meeting 2021 / Virtual	2021
“Overall Assessment of Immune Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors”	Multinational Association of Supportive Care in Cancer Annual Meeting 2021 / Virtual	2021
“The Future is Now: Telemedicine as a Standard of Care”	Melanoma Bridge 2021/Naples, Italy	12/2021
The Clinical Potential of Cellular Therapeutics	ASCO Annual Meeting 2022/ Chicago, IL	06/2022
Progress in Tumor Infiltrating Lymphocytes (TILs)	Immuno-Oncology Summit / Boston, MA	10/2022
Who Gets Adjuvant Therapy in Melanoma?	MSK CME / New York, NY	11/2022
TIL Therapy in Melanoma: The Future is Now	Melanoma Bridge 2022/Naples, Italy	12/2022

## S. **BIBLIOGRAPHY**

### 1. Peer-reviewed Research Articles:

1. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, **Betof AS**, Nixon AB, Spasojevic I, Dewhirst MW. Effect of pazopanib on tumor microenvironment and liposome delivery. *Molecular cancer therapeutics*. 2010,Jun:1798-1808. PMID:PMC2909540
2. Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, Craciunescu O, Stauffer P, Liotcheva V, **Betof AS**, Blackwell K. A phase I/II study of neoadjuvant 13 liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. *International journal of hyperthermia*. 2010,Aug:514-521. PMID:PMC2956498
3. **Betof AS**, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. *British journal of cancer*. 2012,Feb:916-922. PMID:PMC3305967

4. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, **Betof AS**, Nelson ER, Pollak M, Dash RC, Young ME, Freedland SJ. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. *Journal of applied physiology*. 2012,Jul;263-272. PMID:PMC3404704
5. **Betof AS**, Lascola CD, Weitzel, D, Landon C, Scarbrough PM, Devi GR, Palmer G, Jones LW, Dewhirst MW. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. *Journal of The National Cancer Institute*. 2015,Mar:1-5. PMID:PMC4822524
6. **Betof AS**, Nipp RD, Giobbi-Hurder A, Johnpulle, RAN, Rubin K, Rubenstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ. Influence of age on outcomes with immunotherapy in patients with melanoma. *The Oncologist*. 2017,Jul;1-8. PMID:PMC5553960
7. Pollack MH\*, **Betof A\***, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. *Annals of Oncology*. 2018,Jan;29:250-255. PMID:PMC5834131  
**\*Denotes co-first authorship**
8. Rosner S, Kwong E, Shoushtari AN, Friedman CF, **Betof AS^**, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. *Cancer Medicine*. 2018,Mar;7:690-697. PMID:PMC5852343 *^Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*
9. Tokunaga A, Sugiyama D, Maeda Y, **Warner AB^**, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, Nishikawa H. Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids. *Journal of Experimental Medicine*. 2019,Dec;216:2701-2713. PMID:PMC6888983 *^Participated extensively in the conception and design of the study. I was solely responsible for acquiring the data from all patients treated at MSKCC. Participated extensively in analysis and interpretation of data and statistical analysis in collaboration with Dr. Panageas (Attending Statistician). I contributed extensively to drafting of the introduction, methods, results, and discussion sections of the manuscript and critical revision of the manuscript for important intellectual content.*
10. **Betof Warner A**, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK, Wolchok JD, Postow MA, Chapman PB. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. *Journal of Clinical Oncology*. 2020,May;38:1655-1663. PMID:PMC7238490
11. Beattie J, Rizvi H, Fuentes P, Luo J, Schoenfeld A, Lin IH, Postow M, Callahan M, Voss MH, Shah NJ, **Betof Warner A^**, Chawla M, Hellmann MD. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. *Journal for ImmunoTherapy of Cancer*. 2021,Feb;9:e001884. PMID:PMC7878154 *^Participated in conception and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.*
12. Do MH, Barrios DM, Phillips GS, Postow MA, **Warner AB^**, Rosenberg JE, Noor SJ, Markova A, Lacouture ME. Dermatologic infections in cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol*. 2021 Dec; 85(6):1528-1536. PMID: PMC8446092 *^Contributed key melanoma patient cases. Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*

13. Shoushtari AN, Chatila WK, Arora A, Sanchez-Vega F, Kantheti HS, Rojas Zamalloa JA, Krieger P, Callahan MK, **Betof Warner A<sup>^</sup>**, Postow MA, Momtaz P, Nair S, Ariyan CE, Barker CA, Brady MS, Coit DG, Rosen N, Chapman PB, Busam KJ, Solit DB, Panageas KS, Wolchok JD, Schultz N. Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas. *Clinical Cancer Research*. 2021, Apr; 27:2226-2235. PMID: PMC8046739 *^Participated in study design, acquisition of data, analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*
14. Pires da Silva I, Ahmed T, Reijers ILM, Wepler AM, **Betof Warner A<sup>^</sup>**, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study. *Lancet Oncology*. 2021, Jun; 22:836-847. PMID: 33989557 *^Acquired all data from the MSKCC site. Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*
15. Bai X, Hu J, **Betof Warner A<sup>^</sup>**, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Early Use of High-Dose Glucocorticoid for the Management of irAEs Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. *Clin Cancer Res*. 2021 Nov; 27(21):5993-6000. PMID: 34376536 *^Participated extensively in data acquisition from the MSKCC site. Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*
16. Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, Keegan N, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Chapman PB, Shoushtari AN, **Betof AS<sup>^</sup>**, Momtaz P, Merghoub T, Wolchok JD, Panageas KS, Callahan MK. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. *Sci Transl Med*. 2021 Aug; 13(608). PMID: 34433638. *^Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*
17. Hirschhorn D\*, **Betof Warner A\***, Maniyar R, Chow A, Mangarin LMB, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of G1TR engagement by increasing oligoclonal cytotoxic T cell fitness. *JCI Insight*. 2021 Oct 22; 6(20). PMID: PMC8564916.  
**\*Denotes co-first authorship**
18. Halle B\*, **Betof Warner A\***, Zama F, Haydon A, Bhawe P, Dewan A, Ye F, Irlmeier R, Mehta P, Kurtansky N, Lacouture M, Hassel J, Choi J, Sosman J, Otto T, Sullivan R, Mooradian M, Chen S, Dimitriou F, Long G, Carlino M, Menzies A, Johnson D, Rotemberg V. Immune checkpoint inhibitors in patients with preexisting psoriasis: safety and efficacy. *Journal for ImmunoTherapy of Cancer*. 2021 Oct; 9(10). PMID: PMC8506877  
**\*Denotes co-first authorship**
19. Chapman P, Jayaprakasa VS, Panageas K, Callahan M, Postow M, Shoushtari A, Wolchok JD, **Betof Warner A**. Risks and benefits of re-induction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. *Journal for ImmunoTherapy of Cancer*. 2021 Oct; 9(10). PMID: PMC8549669.
20. Wjetunga NA, Boire A, Young RJ, Yamada Y, Wolden S, Yu H, Kris M, Seidman A, **Betof Warner A<sup>^</sup>**, Diaz M, Reiner A, Malani R, Pentsova E, Yang JT. Quantitative Cerebrospinal Fluid Circulating Tumor Cells are a Potential Biomarker of Response for Proton Craniospinal Irradiation for Leptomeningeal Metastasis. *Neuro-Oncology Advances*. 2021 Dec; 3(1):vdab181. PMID: PMC8717892. *^Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*

21. Postow MA, Goldman DA, Shoushtari AN, **Betof Warner A<sup>^</sup>**, Callaha MK, Momtaz P, Smithy JW, Naito E, Cugliari MK, Raber V, Eton O, Nair SG, Panageas KS, Wolchok JD, Chapman PB. Adaptive Dosing of Nivolumab+Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). *Journal of Clinical Oncology*. 2022 April; 40(10): 1059-1067. PMID: PMC8966970. *^Participated in conception and trial design and acquisition of data. I enrolled several patients in this trial. I also participated in analysis and interpretation of data and critical revision of the manuscript for important intellectual content.*
22. Bai X, Shoushtari AN, **Betof Warner A<sup>^</sup>**, Si Lu, Tang B, Cui C, Yang X, Wei X, Quach HT, Cann CG, Zhang MZ, Pallan L, Harvey C, Kim MS, Kasumova G, Sharova T, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Frederick DT, Flaherty KT, Long GV, Menzies AM, Sullivan RJ, Boland GM, Johnson DB, Guo J. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. *British Journal of Dermatology*. 2022 Sep;187(3):401-410. PMID: 35293617. *^Participated extensively in data acquisition from the MSKCC site. Participated in analysis and interpretation of data, critical revision of the manuscript for important intellectual content.*
23. Yang JT, Wijetunga NA, Pentsova E, Wolden S, Young RJ, Correa D, Zhang Z, Zheng J, Steckler A, Bucwinska W, Bernstein A, **Betof Warner A<sup>^</sup>**, Yu H, Kris MG, Seidman AD, Wilcox JA, Malani R, Lin A, DeAngelis LM, Lee NY, Powell SN, Boire A. Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. *Journal of Clinical Oncology*. 2022 Jul; epub ahead of print. PMID: 35802849. *^Participated in trial design, analysis and interpretation of data and critical revision of the manuscript for important intellectual content.*
24. Sia TY, **Betof Warner A<sup>^</sup>**, Noor SJ, Aviki EM, Roche KL. Inflammatory vulvar dermatoses following immune checkpoint inhibitor therapy. *American Journal of Obstetrics and Gynecology*. 2022 Sep; epub ahead of print. PMID: 36084703. *^Contributed patients and medical oncology expertise to this manuscript. Participated in analysis and interpretation of data and critical revision of the manuscript for important intellectual content.*
25. Amaria RN, Postow M, Burton EM, Tezlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, **Betof Warner A<sup>^</sup>**, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto CG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi H. Neoadjuvant relatlimab and nivolumab in resectable melanoma. *Nature*. 2022 Nov; 611(7934):155 PMID: PMC9607737. *^Enrolled multiple patients from the MSKCC site. Participated in acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.*
26. **Betof Warner A**, Tarhini A, Kang B, Nakasato A, Ling YL, Shah R, Tang J, Patel J. Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients. *Melanoma Research*. 2023 Feb; 33(1):38-49. PMID: 36545921
27. Tringale KR, Reiner AS, Sehgal RR, Panageas K, **Betof Warner A<sup>^</sup>**, Postow MA, Moss NS. Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure. *CNS Oncology*. 2023 March; 12(1):CNS93. PMID: PMC9996406. *^Participated in acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content*

## 2. Reviews and Editorials:

1. **Warner AB**, Postow MA. The brim of uncertainty in adjuvant treatment of melanoma. *Lancet Oncology*. 2018, Apr;19:436-437. PMID: 2947764.
2. **Warner AB**, Postow MA. Combination controversies: Checkpoint inhibition alone or in combination for the treatment of melanoma? *Oncology (Norwalk)*. 2018, May;32:228-234. PMID: 29847853

3. Zhang X, Ashcraft KA, **Betof Warner A**, Nair SK, Dewhirst MW. Can exercise-induced modulation of the tumor physiologic microenvironment improve antitumor immunity? *Cancer Research*. 2019,May;79:2447-2456. PMID:PMC7474542
  4. **Warner AB**, McQuade JL. Modifiable host factors in melanoma: Emerging evidence for obesity, diet, exercise, and the microbiome. *Current Oncology Reports*. 2019,Aug;21:72. PMID:PMC7472428
  5. Murciano-Goroff YR\*, **Warner AB\***, Wolchok JD. The future of cancer immunotherapy: Microenvironment-targeting combinations. *Cell Research*. 2020,May;30:507-519. PMID:PMC7264181  
\*Denotes co-first authorship
  6. Ascierto PA, **Betof Warner A**, Blank C, Caraco C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The “great debate” at melanoma bridge 2021, December 2<sup>nd</sup>-4<sup>th</sup>, 2021. *Journal of Translational Medicine*. 2022 May; 20(1):200. PMID: PMC9087170.
  7. Loo K, Smith JW, Postow MA, **Betof Warner A**. Factors determining long-term antitumor responses to immune checkpoint therapy in melanoma. *Front Immunol*. 2022,Jan;12:810388. PMID: PMC8787112
  8. **Betof Warner A**, Corrie PG, Hamid O. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to Future. 2022 Dec; epub ahead of print. PMID: 36485001
3. Chapters:
    1. **Betof Warner A**, Sullivan RJ, Sarnaik A. Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes into View. *American Society of Clinical Oncology Educational Book 42*, 1-8.
  4. Case Reports:
    1. Sudan R, Kasotakis G, **Betof AS**, Wright A. Sleeve gastrectomy strictures: technique for robotic-assisted strictureplasty. *Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery*. 2010,Jul;434-436. PMID: 20655029
    2. Costa BA, Zibara V, Singh V, Hamid O, Gandhi S, Moy AP, **Betof Warner A**. Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus. *Frontiers in Medicine*. 2022 Dec; eCollection. PMID: PMC9773131.
  5. Guidelines:
    1. Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, **Betof Warner A**, Brastianos PK, Cho TA, Clardy SL, Cohen JV, Dietrich J, Dougan M, Doughty CT, Dubey D, Gelfand JM, Guptill JT, Johnson DB, Juel VC, Kadish R, Kolb N, LeBoeuf NR, Linnoila J, Mammen AL, Martinez-Lage M, Mooradian MJ, Naidoo J, Neilan TG, Reardon DA, Rubin KM, Santomasso BD, Sullivan RJ, Wang N, Woodman K, Zubiri L, Louv WC, Reynolds KL. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. *Journal for ImmunoTherapy of Cancer*. 2021,Jul;9:e002890. PMID: PMC8291304
  6. Other (media, podcasts, etc.):

<https://www.today.com/health/cancer-patient-run-nyc-marathon-doctor-t237915>

<https://www.cancernetwork.com/view/dr-allison-betof-warner-outcomes-anti-pd1-therapy-melanoma>

<https://www.vjncology.com/video/gt-jcre5s3o-asco-2019-melanoma-highlights-with-allison-warner/>

<https://www.clinicaloptions.com/oncology/programs/melanoma-clin-impact>

<https://www.onclive.com/view/dr-warner-discusses-findings-from-combii-trial-in-melanoma>

<https://www.youtube.com/watch?v=19uyQNeChsk>

<https://www.larvol.com/blog/asco-clinical-panel-series-melanoma>

<https://touchoncologyime.org/melanoma-treatment-new-insights/>

<https://www.vjoncology.com/video/323m7lctnoo-using-exercise-to-increase-the-efficacy-of-immunotherapies-for-the-treatment-of-melanoma/>

<https://www.vjoncology.com/video/oi21ryg7pke-highlights-from-sitc-2021-on-immunotherapy-in-solid-tumors/>

<https://www.vjoncology.com/video/l1khoq9ehxa-areas-of-unmet-need-for-patients-with-melanoma/>

<https://www.vjoncology.com/video/zv0eqiusjq-the-future-of-cellular-therapies-and-cancer-vaccines-for-the-treatment-of-solid-tumors/>

<https://www.obroncology.com/leading-thoughts/neoadjuvant-anti-pd-1-therapy-should-it-be-standard-for-stage-3-melanoma>

<https://www.obroncology.com/leading-thoughts/another-positive-step-for-til-a-phase-3-trial-at-esmo-2022>

<https://www.obroncology.com/leading-thoughts/neoadjuvant-pd-1-blockade-elicits-high-pcr-in-patients-with-resectable-desmoplastic-melanoma>

<https://www.obroncology.com/leading-thoughts/adjuvant-pembrolizumab-keytruda-for-stage-ii-melanoma-who-needs-it>

<https://www.obroncology.com/leading-thoughts/the-dreamseq-trial-preferred-treatment-sequencing-in-braf-mutant-metastatic-melanoma>

<https://www.obroncology.com/leading-thoughts/after-relativity-047-which-patients-should-receive-the-relatlimab-nivolumab-combination-opdualag>

<https://www.obroncology.com/leading-thoughts/second-line-therapy-options-for-advanced-melanoma-in-patients-who-progress>

<https://www.targetedonc.com/view/where-will-tumor-infiltrating-lymphocyte-therapy-fit-into-the-oncologic-landscape>